Forgotten Antibiotics: an Inventory in Europe, the United States, Canada, and Australia

Total Page:16

File Type:pdf, Size:1020Kb

Forgotten Antibiotics: an Inventory in Europe, the United States, Canada, and Australia REVIEWS OF ANTI-INFECTIVE AGENTS MAJOR ARTICLE Louis D. Saravolatz, Section Editor Forgotten Antibiotics: An Inventory in Europe, the United States, Canada, and Australia Ce´line Pulcini,1 Karen Bush,2 William A. Craig,3 Niels Frimodt-Møller,4 M. Lindsay Grayson,5 Johan W. Mouton,6 John Turnidge,7 Stephan Harbarth,8 Inge C. Gyssens,9,10 and the ESCMID Study Group for Antibiotic Policies 1Centre Hospitalier Universitaire de Nice, Service d'Infectiologie and Universite´ de Nice Sophia-Antipolis, Faculte´ de Me´decine, France; 2Biology Department, Indiana University, Bloomington; 3University of Wisconsin, School of Medicine and Public Health, Madison; 4Department of 5 Clinical Microbiology, Hvidovre Hospital, Copenhagen, Denmark; Infectious Diseases Department, Austin Health and Department of Medicine, Downloaded from University of Melbourne, Victoria, Australia; 6Department of Medical Microbiology, Radboud University Nijmegen Medical Centre and Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, the Netherlands; 7SA Pathology, The University of Adelaide, SA, Australia; 8Geneva University Hospitals and Medical School, Switzerland; 9Department of Medicine, Radboud University Nijmegen Medical Centre and Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, the Netherlands; and 10Hasselt University, Diepenbeek, Belgium http://cid.oxfordjournals.org/ In view of the alarming spread of antimicrobial resistance in the absence of new antibiotics, this study aimed at assessing the availability of potentially useful older antibiotics. A survey was performed in 38 countries among experts including hospital pharmacists, microbiologists, and infectious disease specialists in Europe, the United States, Canada, and Australia. An international expert panel selected systemic antibacterial drugs for their potential to treat infections caused by resistant bacteria or their unique value for specific criteria. Twenty-two of the 33 selected antibiotics were available in fewer than 20 of 38 countries. Economic motives were the major cause for discontinuation of marketing of these antibiotics. Fourteen of 33 antibiotics are at University of Wisconsin-Madison on October 31, 2013 potentially active against either resistant Gram-positive or Gram-negative bacteria. Urgent measures are then needed to ensure better availability of these antibiotics on a global scale. In the European Union, at least 25 000 persons are es- development of new antimicrobial drugs [1, 3–5]. Few timated to die each year from an infection caused by new antibiotics are in the drug development pipeline; in multidrug-resistant bacteria [1]. In the United States, just particular, recent analyses have shown that few anti- one organism, methicillin-resistant Staphylococcus aureus biotics in development have documented in vitro activity (MRSA), kills more Americans every year (approxi- against antibiotic-resistant Gram-negative bacteria [1, 3]. mately 19 000) than emphysema, human immunodefi- Furthermore, the arsenal of available antimicrobial drugs ciency virus/AIDS, Parkinson’s disease, and homicide is becoming smaller because older drugs are disappearing combined [2]. There is a gap between the current from the market or are temporarily unavailable. The worldwide spread of multiresistant bacteria and the ESCMID (European Society of Clinical Microbiology and Infectious Diseases) Study Group for Antibiotic Policies (ESGAP) performed a review in 2006 which Received 25 July 2011; accepted 13 October 2011. Presented in part: poster presentation at the European Congress of Clinical showed that shortages of narrow-spectrum antibacterial Microbiology and Infectious Diseases and oral presentations at the Journe´es drugs forced clinicians to use broad-spectrum drugs, Nationales d'Infectiologie (French Infectious Diseases Society meeting) and Interscience Conference on Antimicrobial Agents and Chemotherapy in 2011. adversely influencing the policies of prudent use [6, 7]. Correspondence: Ce´line Pulcini, MD, PhD, Centre Hospitalier Universitaire de The reasons for shortages and market withdrawals of Nice, Service d'Infectiologie, Hoˆpital l'Archet 1, 151 Route Saint Antoine de older antibiotics are incompletely understood. However, Ginestie`re, BP 3079, 06202 Nice Cedex 3, France ([email protected]). Clinical Infectious Diseases 2012;54(2):268–74 the lack of profit for drugs in limited market areas (small Ó The Author 2011. Published by Oxford University Press on behalf of the Infectious countries) and increasing regulatory requirements and Diseases Society of America. All rights reserved. For Permissions, please e-mail: [email protected]. bureaucracy appear to play a role. Several older, poten- DOI: 10.1093/cid/cir838 tially useful, sometimes ‘‘forgotten’’ antibiotics are not 268 d CID 2012:54 (15 January) d REVIEWS OF ANTI-INFECTIVE AGENTS available in many countries, either never having been in- for multiple resistance to antibiotics: MRSA; vancomycin- troduced or having now been withdrawn [8–10]. In view of intermediate S. aureus (VISA) and vancomycin-resistant S. aureus; the alarming development of resistance in the absence of new vancomycin-resistant enterococci (VRE; eg, Enterococcus faecium); antibiotics, it seemed opportune to collect reliable information on penicillin-resistant Streptococcus pneumoniae; third-generation the availability of currently useful older antibiotics. This study cephalosporin–resistant Enterobacteriaceae (eg, Escherichia coli, had 3 objectives: (1) to select systemic antibiotics (Anatomical Klebsiella pneumoniae); carbapenem-resistant Enterobacteriaceae Therapeutic Chemical [ATC] code J01) with (potential) activity (eg, K. pneumoniae); and carbapenem-resistant nonfermentative on resistant microorganisms and/or having a unique value Gram-negative bacteria (eg, Pseudomonas aeruginosa). for specific criteria and that had at any time been marketed in The selected agents were assessed for their antibacterial ac- Europe, the United States, Canada, and Australia; (2) to assess tivity against the selected bacteria based on actual data available the evidence base of efficacy of these antibiotics in infections in the reference textbook [12] and/or the literature. In the caused by current antibiotic-resistant bacteria, or their unique absence of available in vitro data, the expert panel also took value; and (3) to make an inventory of these selected antibiotics’ into account reasonable assumptions of the activity of some availability in Europe, the United States, Canada, and Australia. agents based on the properties of similar agents (ie, of the same class or with a common mechanism of action) to construct MATERIALS AND METHODS a ‘‘best-case scenario.’’ In vitro activity of each agent against the selected bacteria was Selection of Potentially Useful Antibiotics assigned based on the following approaches: We reviewed the list of all systemic antibacterials (ATC code J01, http://www.whocc.no/atc_ddd_publications/guidelines/)[11] d Actual data on in vitro activity were reviewed whenever that have been approved for human use by the US Food and Drug available. If actual data on in vitro activity were not Administration (FDA) and/or the European Medicines Agency reported for an agent against any of the selected (EMA) and/or in the following countries: Europe (35 countries, pathogens, assumptions were made regarding likely Supplementary Table 1), Canada, and Australia. Exclusion criteria activity based on the properties of the antibiotic class or included (1) antibiotics currently marketed in all countries of of the mechanism of action involved. interest; (2) antituberculous, antifungal, antiparasitic, and antivi- d The assessment of in vitro activity disregarded any known ral drugs; and (3) topical- or inhaled-only antibacterials. Newly potential for cross-resistance and coresistance. approved drugs, such as telavancin, ceftaroline, and fidaxomicin, d Although in vitro activity alone cannot predict in vivo were beyond the scope of our review. efficacy, it was decided not to take into account any Six experts (2 from Europe, 2 from the United States, and available pharmacokinetic data or pharmacokinetics/ 2 from Australia) with clinical/microbiological expertise in pharmacodynamics (PK/PD) analyses when scoring the the field were chosen as assessors. Five of them were authors antibacterial activity of agents because the amount of of a leading reference textbook on antimicrobial drugs [12]. data available was very variable. However, if there was All authors selected the antibiotics for their potential value already information available on nonclinical or clinical against current resistant bacteria and/or for their unique efficacy, these data were factored into the assessment. value for specific criteria, based on the textbook (Kucers’) d The assignment of in vitro activity, which took into [12] and their own experience. account available data together with assumptions based on class properties or mechanisms of action as well as the Assessment of the Potential of These Antibiotics Against route of administration, took the most optimistic view of Currently Resistant Bacteria and of Their Unique Value what the agent might be able to achieve and represents PubMed was searched for literature relevant to the selected a best-case scenario. antibiotics, published until October 2010 inclusive. Based on this literature review and the expert panel advice, the potential The unique value of each of these antibiotics,
Recommended publications
  • Tetracycline and Sulfonamide Antibiotics in Soils: Presence, Fate and Environmental Risks
    processes Review Tetracycline and Sulfonamide Antibiotics in Soils: Presence, Fate and Environmental Risks Manuel Conde-Cid 1, Avelino Núñez-Delgado 2 , María José Fernández-Sanjurjo 2 , Esperanza Álvarez-Rodríguez 2, David Fernández-Calviño 1,* and Manuel Arias-Estévez 1 1 Soil Science and Agricultural Chemistry, Faculty Sciences, University Vigo, 32004 Ourense, Spain; [email protected] (M.C.-C.); [email protected] (M.A.-E.) 2 Department Soil Science and Agricultural Chemistry, Engineering Polytechnic School, University Santiago de Compostela, 27002 Lugo, Spain; [email protected] (A.N.-D.); [email protected] (M.J.F.-S.); [email protected] (E.Á.-R.) * Correspondence: [email protected] Received: 30 October 2020; Accepted: 13 November 2020; Published: 17 November 2020 Abstract: Veterinary antibiotics are widely used worldwide to treat and prevent infectious diseases, as well as (in countries where allowed) to promote growth and improve feeding efficiency of food-producing animals in livestock activities. Among the different antibiotic classes, tetracyclines and sulfonamides are two of the most used for veterinary proposals. Due to the fact that these compounds are poorly absorbed in the gut of animals, a significant proportion (up to ~90%) of them are excreted unchanged, thus reaching the environment mainly through the application of manures and slurries as fertilizers in agricultural fields. Once in the soil, antibiotics are subjected to a series of physicochemical and biological processes, which depend both on the antibiotic nature and soil characteristics. Adsorption/desorption to soil particles and degradation are the main processes that will affect the persistence, bioavailability, and environmental fate of these pollutants, thus determining their potential impacts and risks on human and ecological health.
    [Show full text]
  • Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2
    Infant Antibiotic Exposure Search EMBASE 1. exp antibiotic agent/ 2. (Acedapsone or Alamethicin or Amdinocillin or Amdinocillin Pivoxil or Amikacin or Aminosalicylic Acid or Amoxicillin or Amoxicillin-Potassium Clavulanate Combination or Amphotericin B or Ampicillin or Anisomycin or Antimycin A or Arsphenamine or Aurodox or Azithromycin or Azlocillin or Aztreonam or Bacitracin or Bacteriocins or Bambermycins or beta-Lactams or Bongkrekic Acid or Brefeldin A or Butirosin Sulfate or Calcimycin or Candicidin or Capreomycin or Carbenicillin or Carfecillin or Cefaclor or Cefadroxil or Cefamandole or Cefatrizine or Cefazolin or Cefixime or Cefmenoxime or Cefmetazole or Cefonicid or Cefoperazone or Cefotaxime or Cefotetan or Cefotiam or Cefoxitin or Cefsulodin or Ceftazidime or Ceftizoxime or Ceftriaxone or Cefuroxime or Cephacetrile or Cephalexin or Cephaloglycin or Cephaloridine or Cephalosporins or Cephalothin or Cephamycins or Cephapirin or Cephradine or Chloramphenicol or Chlortetracycline or Ciprofloxacin or Citrinin or Clarithromycin or Clavulanic Acid or Clavulanic Acids or clindamycin or Clofazimine or Cloxacillin or Colistin or Cyclacillin or Cycloserine or Dactinomycin or Dapsone or Daptomycin or Demeclocycline or Diarylquinolines or Dibekacin or Dicloxacillin or Dihydrostreptomycin Sulfate or Diketopiperazines or Distamycins or Doxycycline or Echinomycin or Edeine or Enoxacin or Enviomycin or Erythromycin or Erythromycin Estolate or Erythromycin Ethylsuccinate or Ethambutol or Ethionamide or Filipin or Floxacillin or Fluoroquinolones
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]
  • P147-Bioorgchem-Kanamycin Nucleotidyltransferase-1999.Pdf
    Bioorganic Chemistry 27, 395±408 (1999) Article ID bioo.1999.1144, available online at http://www.idealibrary.com on Kinetic Mechanism of Kanamycin Nucleotidyltransferase from Staphylococcus aureus1 Misty Chen-Goodspeed,* Janeen L. Vanhooke,² Hazel M. Holden,² and Frank M. Raushel*,2 *Department of Chemistry, Texas A&M University, College Station, Texas 77843; and ²Department of Biochemistry, Institute for Enzyme Research, University of Wisconsin, Madison, Wisconsin 53705 Received December 16, 1998 Kanamycin nucleotidyltransferase (KNTase) catalyzes the transfer of the adenyl group from MgATP to either the 4Ј or 4Љ-hydroxyl group of aminoglycoside antibiotics. The steady state kinetic parameters of the enzymatic reaction have been measured by initial velocity, product, and dead-end inhibition techniques. The kinetic mechanism is ordered where the antibiotic binds prior to MgATP and the modified antibiotic is the last product to be released. The effects of altering the relative solvent viscosity are consistent with the release of the products as the rate-limiting step. The pH profiles for Vmax and V/KATP show that a single ionizable group with apK of ϳ8.9 must be protonated for catalysis. The V/K profile for kanamycin as a function of pH is bell-shaped and indicates that one group must be protonated with a pK value of 8.5, while another group must be unprotonated with a pK value of 6.6. An analysis of the kinetic constants for 10 different aminoglycoside antibiotics and 5 nucleotide triphosphates indicates very little difference in the rate of catalysis or substrate binding among these substrates. ᭧ 1999 Academic Press Key Words: kanamycin nucleotidyltransferase; antibiotic modification.
    [Show full text]
  • LC/MS/MS Analysis of Chloramphenicol in Shrimp
    FDA/ORA/DFS No. 4290 Page 1 of 18 LC/MS/MS Analysis of Chloramphenicol in Shrimp Barbara K. Neuhaus,* Jeffrey A. Hurlbut* and Walter Hammack**, * Food & Drug Administration, Pacific Regional Lab - NW, 22201 23RD Drive SE, Bothell, WA 98021 ** Chemical Residue Lab, FL Dept. of Agriculture & Consumer Services, 3125 Conner Blvd., Tallahassee, FL 32399 Abstract Recently our laboratory (FDA, PRL-NW) was given the task of testing the performance of a method developed at the Chemical Residue Lab of the Florida Dept. of Agriculture. This is a liquid chromatographic mass spectrometric (LC/MS/MS) method for qualitative and quantitative detection of chloramphenicol (CAP) in shrimp at the sub parts per billion (ppb) level. Shrimp is pulverized with dry ice, is extracted with ethyl acetate, evaporated with N2, treated with hexane/aqueous NaCl, extracted back into ethyl acetate, dissolved into methanol-water after evaporation, and injected into an LC/MS. CAP eluted from the C18 LC column at about 12.2 min using an acetic acid – ammonium acetate – acetonitrile - water mobile phase. The mass spectrometer was operated in the negative ion mode using selected reaction monitoring, and the precursor ion at m/z = 321 yielded four main product ions of m/z = 257, 194, 176 and 152. The peak area of the m/z 152 peak was used for quantitation. Linear plots were obtained between 0.50 and 10.0 ng/mL CAP. Shrimp tissues were fortified with CAP at 0.10, 0.25, 0.50 and 1.0 ng/mL. Overall recoveries were 85, 92, 85 and 102 % with % RSD values of 9.4, 1.6, 3.1 and 2.5% respectively.
    [Show full text]
  • A New Mutation in 16S Rrna Ofescherichia Coli
    464-466 Nucleic Acids Research, 1995, Vol. 23, No. 3 Q-D/ 1995 Oxford University Press A new mutation in 16S rRNA of Escherichia coli conferring spectinomycin resistance Urban Johanson and Diarmaid Hughes* Department of Molecular Biology, Uppsala University, Biomedical Center, S-751 24 Uppsala, Sweden Received September 24, 1994; Revised and Accepted December 30, 1994 ABSTRACT 1067 1089 A -U We report a novel mutation, Cl 066U in 16S rRNA which was selected for resistance to spectinomycin, an U @- G4C antibiotic which inhibits ribosomal translocation. The U,A,C e- G,U,A minimal inhibitory concentration (MIC) of spectinomy- A cin determined for this mutant (15 pg/ml) is greater U U than with the wild-type plasmid (5 ig/ml) but lower than 1062 1194 with the well known C1192U mutation (>80 pg/ml). The Cl 066U mutation also increases the cells sensitivity to Figure 1. Secondary structure of the upper part of helix 34 of 16S rRNA in fusidic acid, another antibiotic which inhibits transla- Ecoli (24) with the novel C1066U mutation indicated by an open U. In tion at the translocation stage, whereas C1192U is addition, all other known SpcR mutations are shown. The mutations are A1191G,C, Gi 193A in C.reinhardtii chloroplast (25); G1064A (20), A1191C, unchanged relative to the wild type. We discuss why Cl 192U (26) inN.tabacum chloroplast; GI 193A (20) inN.undulata chloroplast the acquisition of resistance to one of these drugs is and C1192U (1), C1192U,G,A (19), G1064U,C,A, G1064U-C1192A, often associated with hypersensitivity to the other.
    [Show full text]
  • Tackling Pristinamycin IIB Problems: Synthetic Studies Toward Some Fluorinated Analogs †
    Proceeding Paper Tackling Pristinamycin IIB Problems: Synthetic Studies toward Some Fluorinated Analogs † Assia Chebieb * and Chewki Ziani-Cherif Department of Chemistry, University Abou-Bekr Belkaid of Tlemcen/Laboratory of Catalysis and Synthesis in Organic Chemistry LCSCO, 13000 Tlemcen, Algeria; [email protected] * Correspondence: [email protected] † Presented at the 24th International Electronic Conference on Synthetic Organic Chemistry, 15 November–15 December 2020; Available online: https://ecsoc-24.sciforum.net/. Abstract: Streptogramins are potent antibiotics against numerous highly resistant pathogens and therefore are used in last-resort human therapy. These antibiotics are formed of both A- and B-group compounds named pristinamycins that differ in their basic primary structures. Although pristina- mycin IIB is among the most interesting antibiotics in this family, it presents numerous problems related to its chemical structure, such as instability at most pH levels, weak solubility in water, and resistance by bacteria. As a response to the need for developing new antimicrobial agents, we have designed a new analog of pristinamycin IIB, based most importantly on the introduction of fluorine atoms. We conjectured indeed that the introduced modifications may solve the above-mentioned problems exhibited by pristinamycin IIB. Our multistep synthetic approach relies on few key reac- tions, namely a Wittig reaction, a Grubbs reaction, and dihydroxy, -difluoro API (Advanced Phar- maceutical Intermediate) synthesis Keywords: streptogramins; pristinamycins IIB; fluorine Citation: Chebieb, A.; Ziani-Cherif, C. Tackling Pristinamycin IIB Problems: Synthetic Studies toward Some Fluorinated Analogs. Chem. The first antibiotic mixture of streptogramin antibiotics was isolated from the pro- Pro. 2021, 3, 107. https://doi.org/ ducer strain Streptomyces graminofaciens from a soil sample in Texas [1].
    [Show full text]
  • Antimicrobial Susceptibility Pattern of Genital Mycoplasmas Among a Group of Pregnant Women
    Alexandria Journal of Medicine (2016) 52, 353–358 HOSTED BY Alexandria University Faculty of Medicine Alexandria Journal of Medicine http://www.elsevier.com/locate/ajme Antimicrobial susceptibility pattern of genital Mycoplasmas among a group of pregnant women Safaa M. Abdel Rahman a, Rania A. Hassan a,*, Noha A. Sakna b a Department of Medical Microbiology and Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt b Department of Gynaecology and Obstetrics, Ain Shams University, Cairo, Egypt Received 10 October 2015; revised 27 November 2015; accepted 23 December 2015 Available online 17 February 2016 KEYWORDS Abstract Mycoplasma hominis (MH) and Ureaplasma urealyticum (UU) are important members of Genital Mycoplasmas; genital Mycoplasmas. They are implicated in urogenital infections and complicated pregnancy Mycoplasma hominis; (chorioamnionitis, preterm delivery, abortion, and preterm birth) as well as bacterial vaginosis Ureaplasma urealyticum; and cervicitis. The administration of antimicrobial agents to pregnant women with preterm rupture Mycoplasma IES kit; of the membranes (PROM) may extend the gestation period and decrease the risks of associated Antimicrobial susceptibility complications and neonatal infections. Despite empirical therapy is the rule in cases suspected to have genital infection in Egypt, the surveillance of the susceptibilities of used antibiotics is manda- tory to ensure treatment efficacy and good prevention of any possible complications. This study aimed to assess the infection rate of genital Mycoplasmas (MH and UU) among pregnant females and their antimicrobial susceptibility pattern to provide a provisional idea about the effectiveness of antibiotics used empirically to treat cases of genital infections in pregnant women. High vaginal swabs of 50 pregnant females were examined using Mycoplasma IES kit, for identification of UU and MH.
    [Show full text]
  • Swedres-Svarm 2019
    2019 SWEDRES|SVARM Sales of antibiotics and occurrence of antibiotic resistance in Sweden 2 SWEDRES |SVARM 2019 A report on Swedish Antibiotic Sales and Resistance in Human Medicine (Swedres) and Swedish Veterinary Antibiotic Resistance Monitoring (Svarm) Published by: Public Health Agency of Sweden and National Veterinary Institute Editors: Olov Aspevall and Vendela Wiener, Public Health Agency of Sweden Oskar Nilsson and Märit Pringle, National Veterinary Institute Addresses: The Public Health Agency of Sweden Solna. SE-171 82 Solna, Sweden Östersund. Box 505, SE-831 26 Östersund, Sweden Phone: +46 (0) 10 205 20 00 Fax: +46 (0) 8 32 83 30 E-mail: [email protected] www.folkhalsomyndigheten.se National Veterinary Institute SE-751 89 Uppsala, Sweden Phone: +46 (0) 18 67 40 00 Fax: +46 (0) 18 30 91 62 E-mail: [email protected] www.sva.se Text, tables and figures may be cited and reprinted only with reference to this report. Images, photographs and illustrations are protected by copyright. Suggested citation: Swedres-Svarm 2019. Sales of antibiotics and occurrence of resistance in Sweden. Solna/Uppsala ISSN1650-6332 ISSN 1650-6332 Article no. 19088 This title and previous Swedres and Svarm reports are available for downloading at www.folkhalsomyndigheten.se/ Scan the QR code to open Swedres-Svarm 2019 as a pdf in publicerat-material/ or at www.sva.se/swedres-svarm/ your mobile device, for reading and sharing. Use the camera in you’re mobile device or download a free Layout: Dsign Grafisk Form, Helen Eriksson AB QR code reader such as i-nigma in the App Store for Apple Print: Taberg Media Group, Taberg 2020 devices or in Google Play.
    [Show full text]
  • (ESVAC) Web-Based Sales and Animal Population
    16 July 2019 EMA/210691/2015-Rev.2 Veterinary Medicines Division European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Sales Data and Animal Population Data Collection Protocol (version 3) Superseded by a new version Superseded Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of content 1. Introduction ....................................................................................................................... 3 1.1. Terms of reference ........................................................................................................... 3 1.2. Approach ........................................................................................................................ 3 1.3. Target groups of the protocol and templates ......................................................................... 4 1.4. Organization of the ESVAC project ...................................................................................... 4 1.5. Web based delivery of data ................................................................................................ 5 2. ESVAC sales data ............................................................................................................... 5 2.1.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • MACROLIDES (Veterinary—Systemic)
    MACROLIDES (Veterinary—Systemic) This monograph includes information on the following: Category: Antibacterial (systemic). Azithromycin; Clarithromycin; Erythromycin; Tilmicosin; Tulathromycin; Tylosin. Indications ELUS EL Some commonly used brand names are: For veterinary-labeled Note: The text between and describes uses that are not included ELCAN EL products— in U.S. product labeling. Text between and describes uses Draxxin [Tulathromycin] Pulmotil Premix that are not included in Canadian product labeling. [Tilmicosin Phosphate] The ELUS or ELCAN designation can signify a lack of product Erythro-200 [Erythromycin Tylan 10 [Tylosin availability in the country indicated. See the Dosage Forms Base] Phosphate] section of this monograph to confirm availability. Erythro-Med Tylan 40 [Tylosin [Erythromycin Phosphate] General considerations Phosphate] Macrolides are considered bacteriostatic at therapeutic concentrations Gallimycin [Erythromycin Tylan 50 [Tylosin Base] but they can be slowly bactericidal, especially against Phosphate] streptococcal bacteria; their bactericidal action is described as Gallimycin-50 Tylan 100 [Tylosin time-dependent. The antimicrobial action of some macrolides is [Erythromycin Phosphate] enhanced by a high pH and suppressed by low pH, making them Thiocyanate] less effective in abscesses, necrotic tissue, or acidic urine.{R-119} Gallimycin-100 Tylan 200 [Tylosin Base] Erythromycin is an antibiotic with activity primarily against gram- [Erythromycin Base] positive bacteria, such as Staphylococcus and Streptococcus Gallimycin-100P Tylan Soluble [Tylosin species, including many that are resistant to penicillins by means [Erythromycin Tartrate] of beta-lactamase production. Erythromycin is also active against Thiocyanate] mycoplasma and some gram-negative bacteria, including Gallimycin-200 Tylosin 10 Premix [Tylosin Campylobacter and Pasteurella species.{R-1; 10-12} It has activity [Erythromycin Base] Phosphate] against some anaerobes, but Bacteroides fragilis is usually Gallimycin PFC Tylosin 40 Premix [Tylosin resistant.
    [Show full text]